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Background: The presence of echolucent carotid plaques as defined by low ultrasound grey-scale median (GSM)
is associated with a higher risk of stroke and myocardial infarction. Betablockers have shown possible
anti-atherosclerotic effects. The aim of the present study was to determine if there is an association between carotid
plaque GSM and treatment with betablockers.
Methods: The GSM of the carotid plaques of 350 patients who underwent carotid endarterectomy (CEA) for
asymptomatic (n = 113) or symptomatic (n = 237) carotid disease was measured. Patients were divided in two
groups based on the absence/presence of an on-going long-term (i.e. at least 6 months) oral treatment with
betablockers at the time of CEA.
Results: The prevalence and type of preoperative neurological symptoms were similar in the two groups. Patients
with betablockers had more frequently arterial hypertension (P < .0001), diabetes (P = .035) and a higher BMI
(P = .0004), while patients without betablockers were most frequently smokers (P = .017).
Patients with betablockers revealed to have higher GSM (37.79 ± 25 vs 32.61 ± 23.50 P = .036). Echogenic plaques
(i.e. with GSM > 30) showed to be more frequent in patients with betablockers also after correction for age, gender,
the occurrence of preoperative symptoms, diabetes, hypertension, smoking and statins use (P = .024).
Conclusions: These results suggest the use of standardized ultrasound techniques as an important tool in
evaluating the effect of anti-atherosclerotic medications and underline the need of.further prospective randomized
studies on larger patient cohorts in order to confirm these results.
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B-mode ultrasound of the carotid arteries has shown to
be a valid method for non-invasive assessment of the
presence and clinical burden of atherosclerosis [1,2].
There is today a general consensus that the risk of an
atherosclerotic plaque to become symptomatic is not
only dependent on the degree of stenosis but also on its
composition.
The possibility to assess carotid plaque morphology on
ultrasound images in a standardized way has been widely
explored in the last decade mostly by the use of the
grey-scale median (GSM). Echolucent plaques, which
have shown to be rich in lipids and macrophages as* Correspondence: giuseppe.asciutto@med.lu.se
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unless otherwise stated.expression of a high degree of intrinsic plaque inflamma-
tion [3-5].
Treatment with statins has already shown to influence
plaque composition and its ultrasound appearance [6,7].
As perioperative beta-blockade became standard therapy
in the prevention of cardiovascular (CV) events in patients
undergoing vascular surgery, the question about their
mechanisms of action was raised. Several hypotheses such
that of a reduced inflammatory response which leads to
the atherogenic process [8], or the effects by the promo-
tion of laminar flowpatterns [9] have been advanced.
Furthermore, betablockers have been shown to have
an inhibitory effect on early stages of carotid atheroscler-
osis development [10,11] and a long-term exposition to
betablockershas been associated to a milder degree of in-
flammation in carotid plaques [12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sible influence of long-term treatment with betablockers
on the GSM of carotid plaques of patients using it as a
surrogate marker of the effects on plaque composition.
Methods
Study population
410 patients who underwent carotid endarterectomy
(CEA) between October 2005 and December 2012 at
our Vascular Department were identified for inclusion in
this study. Informed consent was given by all patients
and the study was approved by the local ethical commit-
tee (Regional ethical committee, Lund - decision number
472/2005).
Sixty patients were excluded because of the presence
of extremely calcified plaques not allowing a GSM meas-
urement, accounting for a total of 350 analysed plaques.
Patients with ipsilateral carotid artery occlusion, radi-
ation carotid artery stenosis or restenosis after previous
CEA or endovascular treatment were excluded. An inde-
pendent accredited neurologist clinically assessed all pa-
tients preoperatively. Patients were considered to have
asymptomatic disease if they had no amaurosis fugax
(AF), transient ischemic attacks (TIAs) or stroke in the
6 months prior to surgery. Indications for surgery were
described in detail elsewhere [13].
Information about comorbidities and past medical his-
tory were obtained through standardized preoperative
interviews and review of the medical records. Comorbid-
ities such as hypertension, diabetes, smoking, as well as
the body mass index (BMI), serum levels of triglycerides
(TG), low-density lipoproteins (LDL), high-density lipo-
proteins (HDL) were recorded.
The Swedish national medication register was analysed
to identify and determine the presence of any on-going
treatment with betablockers at the time of surgery and
its duration. This is a nationwide healthcare database
where all the prescriptions are registered. Long-term
treatment was assumed in patients receiving betablock-
ers of any type and dose for at least six months before
surgery, regardless of the primary indication. All patients
undergoing CEA were routinely prescribed long-term
treatment with statins (simvastatin 40 mg) and acetyl-
salicylic acid (75 mg) or clopidogrel (75 mg) daily, if this
treatment was not already in use.
B-mode ultrasound and measurement of GSM
One day before surgery, carotid ultrasound investigation
was performed by a certifies sonographer using an Acu-
son Sequoia (Acuson, Mountain View, CA, USA) with
a 6 MHz-probe according to a previously published
method [14].
All images for measurement of GSM in the plaque
were obtained in the longitudinal projection showing thelargest plaque present. GSM analysis was performed on
a longitudinal image showing the largest plaque present
in a predefined window consisting of three centimeters
of the common carotid artery (CCA), the bulb and one
centimeter of the internal- and external carotid artery
(ICA and ECA respectively).
A video colour flow sequence was recorded in order to
help in outlining the plaque for GSM analysis. All GSM
measurements were performed by a single specially trained
and experienced sonographer (G.A.) with blinded patient
information, including current medications. An intravaria-
bility study (n = 20) for measurement of GSM showed that
the method had good reproducibility, with a coefficient of
variation of 7% and absolute difference between measure-
ments was 1.5 units.
Measurement of GSM was done using Adobe Photo-
shop 12.0 (Adobe System incorporated, San Jose, CA,
USA) with a method previously described [15]. In brief,
the method is based on the standardization of images
where black, represented by lumen, and white, repre-
sented by the adventitia, are given the values 0 and 190,
respectively. After linear adjustment of the grey scale in
the images according to these values, the plaque was
outlined. The median value of the grey scale, the GSM
value, in this outlined area was used to define the degree
of echogenicity in the plaque.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation (SD) when not stated otherwise, while categor-
ical variables are presented as percentages.
As the GSM values of the entire study population were
non-normally distributed, its median was used to divide
plaques in to echolucent (≤30) and echogenic (>30).
Mann-Whitney U test and Spearman’s rank correlation
were used for GSM analysis for the same reason.
Simple and multiple linear regressions were used to ex-
plore the relationship between two or more continuous
variables, while logistic regression was used in case of di-
chotomous variables. The regression model included age,
gender, hypertension, diabetes, tobacco use, pre-operative
symptoms and use of statins. A P-value of < .050 was con-
sidered statistically significant. Statistical analysis was per-
formed using SPSS 22.0 (IBM Corp., Amonk, NY: USA).
Results
The plaques of three-hundred and fifty patients (70 ±
9 years, 245 males) undergoing CEA were included.
Two-hundred and thirty seven (68%) plaques were asso-
ciated with ipsilateral hemispheric symptoms while 113
(32%) were not.
The study population was divided into two subgroups
based on the absence (n = 197) or presence (n = 153) of
long-term treatment with betablockers at the time of
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(metoprolol 72%, atenolol 20%, bisoprolol 4%, others
4%), with a mean time of treatment duration was of
53.2 ± 22.3 months. Overall 87% of the subjects were on
statins for at least 1 month before CEA (mean treatment
time 46.5 ± 23 months).
As shown in Table 1, patients with betablockers had
more frequently arterial hypertension (P < .0001), diabetes
(P = .035) and a higher BMI (P = .0004), while patients with-
out betablockers were most frequently smokers (P = .017).
Age, the degree of stenosis, the incidence and type of pre-
operative neurological symptoms, the time between symp-
toms and CEA as well as the serum levels of TG, LDL,
HDL were not different between the two groups of patients.
As shown in Figure 1, patients with betablockers re-
vealed to have higher GSM than those without (37.79 ±
25 vs 32.61 ± 23.50 P = .036).
Echogenic plaques (i.e. with GSM > 30) were more fre-
quent in patients with betablockers . This finding could
be confirmed after regression analysis using age, gender,
the occurrence of preoperative symptoms, diabetes,
hypertension, smoking, BMI and statins use as con-






Age (years) 69.91 ± 8.79 70.79 ± 8.43 .364†
Male 69% (137) 71% (108) .906*
BMI 25.9 ± 3.3 27 ± 3.6 .0004†
Diabetes 20% (40) 30% (46) .035*
Hypertension 58% (115) 89% (137) < .0001*
Smoking
.017*
No 18% (35) 22% (33)
Current 37% (73) 23% (35)
Ex 45% (89) 56% (85)
Statins 85% (167) 89% (136) .274*
Degree of stenosis (%) 85.6 ± 11.8 84.6 ± 12.2 .320†
Symptoms
Type of symptoms 72% (141) 63% (96)
.618†
AF 20% (28) 19% (18)
TIA 35% (50) 42% (40)
Stroke 45% (63) 40% (38)
Time to surgery – days 25 ± 32.4 21.8 ± 22.6 .945†
GSM 32.6 ± 23.5 37.8 ± 25 .036†
Patients are grouped based on the use of beta-blockers.
Categorical variables are presented as percentages with absolute numbers
between parenthesis. Continuous variables are presented as mean
(standard deviation).
AF = amaurosis fugax; BMI = Body mass index; TIA = transient ischemic attack; Time
to surgery = time between symptoms (if present) and operation. * = Pearson’s
Chi-square; †=Mann-Whitney U testDiscussion
The main finding of this study was that long-term treat-
ment with betablockers was associated with higher GSM
values of carotid plaques. The degree of stenosis and
plaque morphology, defined by its structure and surface
characteristics, are thought to play an important role in
the pathogenesis of CV events. An unstable carotid
plaque is associated with a thinning of the fibrous cap,
infiltration of inflammatory cells leading to surface ul-
ceration, and plaque rupture [16,17]. An early identifica-
tion of these features suggesting plaque instability would
therefore be very useful for treatment. Recent ultrasound
studies based on a computerized measurement of the
GSM value of the carotid plaque demonstrated that a
low GSM value, reflecting echolucent lesions, was asso-
ciated with an increased risk of cerebrovascular events
and may represent a good predictor of carotid plaque
behavior [18], leading to suggest GSM measurement as a
complementary tool in the planning of the treatment of
carotid artery stenosis in addition to neurological symp-
toms and the degree of stenosis [19].
The possible anti-atherosclerotic effects of several drugs
have been investigated. Statins are probably one of the
most studied with its use leading to increased GSM both
in carotid and coronary plaques [20,21]. This could be an
expression of a more stable plaque phenotype and can be
used to monitor their effects on atherosclerotic lesions.
Betablockers have been increasingly used in vascular
surgery because of their suggested effect in reducing the
occurrence of postoperative CV events as suggested by
several treatment guidelines [22,23]. However their indis-
criminate use in surgical patients, independently of their
CV risk, has been strongly questioned [24]. Even if treat-
ment with betablockers has shown to be associated with
possible anti-atherosclerotic effects on early stages of ca-
rotid lesion development [10,11], their mechanisms of ac-
tion are still unknown. Their antiatherogenic effects could
be the result of the reduced endothelial injury related to a
decrease in heart rate and pulse pressure, which produce
an increase in shear stress and a decrease in pressure re-
lated cycling stretching of the artery [25]. Hampering the
sympathetic nervous system could also contribute to the
antiatherogenic effects of betablockers preventing endo-
thelial injury and reducing the vessel wall permeability to
LDL particles [26]. This results in a milder degree of lipid
accumulation that, in its turn, produces a more echogenic
plaque pattern on ultrasound [3,27].
A higher degree of intra-plaque inflammation as
expressed by a higher content of macrophages [4], and
pro-inflammatory cytokines [28] has been shown to lie
behind the echolucent aspects of carotid plaques. A pos-
sible intrinsic anti-inflammatory action of betablockers,
as supported by the results of an animal study [29],
could also explain our findings of higher GSM, i.e. more
Figure 1 Box-plots showing the GSM values according to the absence or presence of a long-term treatment with betablockers at the
time of surgery.
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with betablockers.
Several lines of evidence suggest that this could pos-
sibly reflect a positive effect on atherosclerotic lesions,
which, in turn, are associated with a lower risk for devel-
opment of clinical events [18,30]. To the best of our
knowledge, this is the first study reporting an ultrasound
verification of a stabilising effect of the long-term treat-
ment with betablockers on advanced atherosclerotic
disease.
As previously reported [12], we could confirm in a lar-
ger cohort of patients that those on long-term treatment
with betablockers revealed to have more often arterial
hypertension, diabetes and a higher BMI. This couldTable 2 Simple linear regression analysis
B St. error Beta t P-value
Age .174 .150 .062 1.157 .248
Gender 3.114 2.830 .059 1.100 .272
BMI -.291 .373 -.042 -.779 -.437
Preoperative symptoms -1.070 2.778 -.021 -.385 .700
Diabetes 3.878 3.011 .069 1.288 .199
Hypertension 2.138 2.869 .040 .745 .457
Smoking
No + Yes 0/Ex 1 -1.299 2.598 -.027 -.500 .617
No + Ex 0/Yes 1 2.561 2.810 .049 .912 .363
Statins -1.690 3.810 -.024 -.444 .658
Betablockers 5.177 2.605 .106 1.987 .048
GSM as dependent continuous variable.suggest a different phenotype than those without, which
could be representative of a metabolic syndrome.
A wide range of GSM threshold values, going from 25
to 74, are proposed in the literature to distinguish echo-
lucent from echogenic plaques [18,19,28]. These various
cut-off points may be attributable to different choices
for the standardization of the reference values (lumen
and adventitia). For the purpose of the present study, we
decided to use the median GSM value of the entire study
cohort as cutoff value (i.e. 30).
Moreover, GSM analysis represents a median value of
the whole atherosclerotic area and it may not necessarily
reflect the presence of particular regional components.
New techniques, such stratified analysis [31] andTable 3 Multiple linear regression analysis
B St. error Beta t P-value
Constant 16.698 19.970 .840 .401
Age .249 .174 .089 1.430 .154
Gender 2.830 2.907 .054 .974 .331
BMI -.333 .399 -.048 -.833 .405
Preoperative symptoms -1.693 2.928 -.033 -.578 .563
Diabetes 3.641 3.108 .065 1.171 .242
Hypertension -.707 3.125 -.013 -.226 .821
Smoking
No + Yes 0/Ex 1 1.592 3.565 .033 .447 .655
No + Ex 0/Yes 1 5.810 4.127 .111 1.408 .160
Statins -1.496 3.872 -.021 -.386 .699
Betablockers 5.786 2.833 .118 2.042 .042
GSM as dependent continuous variable.
Table 4 Simple logistic regression analysis
B St. error Wald P-value Exp(B) CI for Exp(B)
Lower bound Upper bound
Age .019 .013 2.380 .123 1.019 .995 1.045
Gender .568 .237 5.718 .017 1.765 1.108 2.811
BMI -.031 .031 .984 .321 .970 .913 1.030
Preoperative symptoms .041 .229 .033 .856 1.042 .666 1.632
Diabetes .311 .250 1.547 .214 1.365 .836 2.229
Hypertension .341 .237 2.067 .150 1.407 .883 2.240
Smoking
No + Yes 0/Ex 1 -.413 -.215 3.682 .055 .662 .434 1.009
No + Ex 0/Yes 1 .365 .233 2.443 .118 1.440 .912 2.275
Statins -.194 .315 .378 .539 .824 .444 1.528
Betablockers .550 .218 6.375 .012 1.734 1.131 2.657
GSM ≤ 30 vs > 30 as dependent categorical variable.
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to solve this problem, but their application on large scale
have been limited by their complexity so far.
The different therapeutic regimes in terms of betablocker
type, absolute dose and duration are bringing heterogeneity
to the study population, but tend to reflect clinical practice.
Furthermore, the small sample size and the predominant
use of metoprolol do not allow any meaningful analysis of
the possible influence of the drug type on GSM.
Other simultaneous medical treatments, such as statins
and immunotherapy [33], as well as the presence of
known and unknown comorbidities could have influenced
our findings. The association between long-term treat-
ment with betablockers and higher GSM was, neverthe-
less, confirmed after statistical correction for statins useTable 5 Multiple logistic regression analysis
B St. error Wald
Constant -.874 1.738 .253
Age .025 .015 2.785
Gender .508 .250 4.131
BMI -.029 .035 .698
Preoperative symptoms -.014 .250 .003
Diabetes .291 .266 1.192
Hypertension .071 .267 .071
Smoking
No + Yes 0/Ex 1 -.204 .303 .454
No + Ex 0/Yes 1 .488 .355 1.886
Statins -.202 .330 .373
Betablockers -.643 .244 6.926
GSM ≤ 30 vs > 30 as dependent categorical variable.and the presence of a known hypertension and diabetes.
However, the absence of accurate data on blood pressure
and HbA1c can be seen as a limitation of this study.
Its non-randomized design is to see as a limitation of
this study and should be overcame in order to be able to
make general recommendation about the use of a long-
term betablockers treatment in patients with advanced
atherosclerotic lesions. Furthermore, the retrospective
nature of the study with the absence of a GSM measure-
ment upon the initiation of the betablockers treatment
does not allow any kind of speculation about their
mechanism of action or their possible direct influence
on plaque composition. Prospective, randomized studies,
above all on patients with asymptomatic carotid disease
are therefore required for confirmatory purposes.P-value Exp(B) CI for Exp(B)
Lower bound Upper bound
.615 .417
.095 1.025 .996 1.056
.042 1.662 1.018 2.712
.403 .972 .908 1.040
.956 .986 .604 1.610
.275 1.338 .793 2.255
.790 1.074 .636 1.813
.500 .815 .450 1.476
.170 1.629 .812 3.267
.541 .817 .428 1.561
.008 .526 .325 .849
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The findings of the current study support the use of stan-
dardized ultrasound techniques as a means of evaluating
the effect of anti-atherosclerotic medications. Moreover,
our conclusions suggest other effects of betablockers in
treating CV diseases beyond hemodynamics. Further stud-
ies are needed in order to confirm these results.
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